About

Sean P. Nolan is an Independent Director of Ventas (since 2019) and a member of the Compensation Committee and the Nominating, Governance and Corporate Responsibility Committee. He brings 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur.

Mr. Nolan previously served as CEO of AveXis, which he grew from four employees to a fully integrated global public company that was ultimately sold to Novartis for $8.7 billion.

Roles

Ventas, Inc.
Independent Director · Current role
2019–present
Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
Chief Executive Officer (since 2022); Chairman of the Board (since 2020)
Nolan Capital, LLC
President · An investment fund (since 2019).
AveXis, Inc. (formerly NASDAQ: AVXS)
President and Chief Executive Officer · Gene therapy company sold to Novartis for $8.7 billion.
2015-2018
InterMune, Inc. (formerly NASDAQ: ITMN)
Chief Business Officer · Biopharmaceutical company.
2013-2015
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
Chief Commercial Officer · Pharmaceuticals company.
2011-2012
Lundbeck, Inc.
Chief Commercial Officer and President · U.S. affiliate of H. Lundbeck A/S, a Danish pharmaceuticals company.
2009-2010

External Roles

Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
Director / Chairman of the Board
Neoleukin Therapeutics (now Neurogene, Inc.) (NASDAQ: NLTX)
Director
2019-2020
Aquinox Pharmaceuticals, Inc. (formerly NASDAQ: AQXP)
Director
2015-2019

Also at Ventas, Inc.

Related

See how VectorShift works for your firm

Request Demo